Glenmark USA Launches Generic Methylene Blue Injection in the U.S. Market

Glenmark Pharmaceuticals Inc., USA has launched its Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial in the United States. Announced on June 17, 2026, the product is a bioequivalent and therapeutically equivalent alternative to the reference listed drug, ProvayBlue® Injection (manufactured by Provepharm SAS). Key Highlights: Product & Indication: Methylene Blue Injection USP (50 mg/10 mL), a critical hospital-administered injectable. Target Market: The U.S. institutional sector, focusing on healthcare facilities and hospitals. Addressable Market: According to IQVIA data, the reference product (ProvayBlue) generated approximately $19.0 million in U.S. sales over the 12-month period ending April 2026. Strategic Significance: Portfolio Expansion: The launch strengthens Glenmark’s institutional generics portfolio in North America, a key growth driver for the company. Affordability & Access: Aligns with Glenmark's strategic mandate to expand access to high-quality, affordable medicines for U.S. healthcare institutions and their patients. Market Penetration: By offering a therapeutically equivalent alternative, Glenmark is positioned to capture a meaningful share of this niche, high-value injectable market. Outlook: This launch reinforces Glenmark's growing footprint in the U.S. complex injectables and institutional segment. Success in this market will rely on robust distribution networks, competitive pricing strategies, and strong relationships with Group Purchasing Organizations (GPOs) and hospital networks. $GLENMARK